ANKRD55 and myeloid sarcoma: On the whole, current evidence explains genetic risk for MS and RA conferred by ANKRD55 SNPs in terms of a cis CpG methylation-dependent mechanism to increase the expression of two genes, ANKRD55 and IL6ST, in CD4+ T lymphocytic cells.